Tonix Pharm Holdings (TNXP) Stock Price, Quote & News

Company Profile

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company d...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Website: www.tonixpharma.com

Address:

200 Connell Drive, Suite 3100, Berkeley Heights, United States

JuggernautRaider Jun. 29 at 3:09 AM

$SLS another million shares for a CEO who has not yet led a single AML drug to approval? That is the dirtiest of D words in healthcare investing: DILUTION!!! 🤮 Look I love the SLS story as much as the next guy… but there are other stocks that could 5-10x like $TNXP $ALT and maybe $CGTX

6 · Reply

glbeacher Jun. 29 at 3:03 AM

$TNXP f u to stino. you are living in a dreamworld.

0 · Reply

glbeacher Jun. 29 at 2:47 AM

$TNXP F U jugger. we don't need your worthless data and sure don't need to pay for it. maybe a penny, loser.

0 · Reply

JuggernautRaider Jun. 29 at 1:23 AM

$TNXP the GHCA guy has spoken @alphaonetrading … 🤯 https://www.linkedin.com/posts/jeff-conroy-80a39323_gaslighting-medicines-3-most-dismissive-activity-7477167846192766976-tn5A Latest Symphony sales data for @dachshund36 & friends: Week Ending TRx NRx TRx ($ K) $/script ($ K) Implied Annual Gross Run Rate $ K 2/6/2026 285 249 451 1.58 23,476 2/13/2026 371 327 598 1.61 31,088 2/20/2026 384 341 639 1.66 33,209 2/27/2026 401 347 642 1.60 33,374 3/6/2026 462 365 750 1.62 38,984 3/13/2026 483 384 755 1.56 39,262 3/20/2026 572 465 935 1.63 48,630 3/27/2026 525 401 799 1.52 41,548 4/3/2026 515 397 811 1.57 42,161 4/10/2026 548 404 829 1.51 43,100 4/17/2026 580 428 950 1.64 49,407 4/24/2026 616 449 994 1.61 51,695 5/1/2026 697 535 1,129 1.62 58,723 5/8/2026 706 509 1,141 1.62 59,339 5/15/2026 677 499 1,092 1.61 56,771 5/22/2026 806 553 1,318 1.64 68,544 5/29/2026 703 492 1,132 1.61 58,885 6/5/2026 840 603 1,312 1.56 68,230 6/12/2026 859 579 1,394 1.62 72,491

1 · Reply

Mstrong87 Jun. 29 at 12:25 AM

$TNXP

0 · Reply

Hadog78 Jun. 28 at 10:40 PM

$TNXP

0 · Reply

gc358 Jun. 28 at 9:03 PM

$TNXP Ok, you're officially blocked. You have posted the same message at least 5 times to 5 other stocks from what I can see on the GALT board. You're obviously spamming.

2 · Reply

WARBUD Jun. 28 at 8:48 PM

$TNXP LET’S TALK ABOUT FRIDAY AND WHAT TO WATCH MONDAY I used WARMACHINE to replay the 1-minute bars and Level 1 order book (NBBO) data to get a full read on what happened. Last 10 mins were crazy. Follow with me... FIRST, rewind one day to Thursday, June 25. Don’t forget this post from Thursday I re-shared. In hindsight, it feels like 102 was calling the setup a day early. That was a green moonbeam straight into resistance, and it got stuffed. Then Friday rolls around. I was gone traveling, so I did not watch the order book live...got back home at the last 15 minutes! The action started around 2:13 PM CT. Then the real surge hit late. Roughly 450K shares traded during the LAST 10 minutes of the day That was not quiet closing drift....that was a real fight into the bell. So where does that leave us? Speculating only, but I see a few possibilities: 1. The ATM lifted and 102 broke out of the gate hard. 2. News may have hit behind the scenes and we get an 8-K Monday. 3. Both. I have been PREACHING the last few days about what I’m seeing on the order book and the similarities to the PDUFA run when we were stuck at this same exact level for months. You can search my history from Jan 2025 through March 2025. When the ATM lifted, we ran. But this feels different. I do not remember that big of a surge in a 10-minute window last time. Back then, the ATM lifted and we stair-stepped into the 20s. So Monday, I’m watching two things: 1. SEC filings. TNXP is notorious for dropping 8K Bombs in the 6:00–6:30 AM CT window. If news is coming, that is the window I’m watching before the open. 2. The order book. Do we still see those 1100 share blocks sitting on the ask? (see my previous posts) Big day tomorrow. FUD Bears never listen.. ;)

1 · Reply

Bobear12 Jun. 28 at 7:34 PM

$TNXP friends help me with this dispute on your neighboring message board. Thanks! $GALT ThomasLD your $2B low end estimate prior to BO would make the price around $30 p/share. I have expressed that is no low of an estimate in my opinion. I know how to prove it to you …TIME. Yes Timewill prove me right. I suggest a!7B 50% partnership. Message Board who’s estimate do you support? Bo-nos🇱🇷

0 · Reply

Willy_Nilly Jun. 28 at 5:30 PM

$TNXP Their peak sales estimate isn't crazy. Raymond James reportedly sees roughly a $400M-$500M peak sales opportunity for TONMYA. Frankly, I think that's a fairly conservative-to-moderate estimate. It's nowhere near a blue-sky blockbuster assumption. Given: roughly 10 million U.S. fibromyalgia sufferers, persistent dissatisfaction with existing therapies, widespread off-label cyclobenzaprine use, TONMYA's sleep differentiation, a few hundred million dollars in annual sales is not an outrageous thesis if execution continues to improve.

1 · Reply

Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James

Jun 15, 2026, 7:00 AM EDT - 13 days ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jun 11, 2026, 7:00 AM EDT - 17 days ago

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

2026-06-08T11:14:39.000Z - 20 days ago

Tonix Pharmaceuticals secures second commercial agreement for Tonmya

Jun 8, 2026, 7:00 AM EDT - 20 days ago

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Jun 1, 2026, 7:00 AM EDT - 27 days ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-05-28T21:29:12.000Z - 4 weeks ago

Tonix presents data from analysis of opioid use in adults with fibromyalgia

May 28, 2026, 4:30 PM EDT - 4 weeks ago

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

2026-05-27T13:00:38.000Z - 4 weeks ago

Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology

May 27, 2026, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

May 27, 2026, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-05-26T11:57:59.000Z - 4 weeks ago

Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia

May 26, 2026, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

May 19, 2026, 1:35 PM EDT - 5 weeks ago

Tonix Pharmaceuticals Holding Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 17, 2026, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Holding Slides: 2nd Richard Slayman Clinical Xenotransplantation Workshop presentation

May 14, 2026, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

May 12, 2026, 4:30 PM EDT - 6 weeks ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

2026-05-11T23:47:32.000Z - 6 weeks ago

Tonix Pharmaceuticals reports Q1 EPS ($2.93) vs. ($2.84) last year

May 11, 2026, 4:30 PM EDT - 6 weeks ago

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights

May 11, 2026, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Holding Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Holding Earnings release: Q1 2026

2026-05-07T04:37:07.000Z - 7 weeks ago

Tonix Pharmaceuticals secures commercial payer coverage for Tonmya

May 6, 2026, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

2026-05-04T09:45:07.000Z - 7 weeks ago

Tonix Pharmaceuticals initiated with a Buy at TD Cowen

2026-04-29T15:52:42.000Z - 2 months ago

Tonix Pharmaceuticals says on track to initiate Phase 2 study of TNX-4800

Apr 29, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

2026-04-15T11:14:23.000Z - 2 months ago

Tonix Pharmaceuticals publishes Tonmya study data findings

Apr 15, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

Apr 7, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-03-31T11:25:26.000Z - 3 months ago

Tonix Pharmaceuticals presents TNX-4800 data, to initiate adaptive field study

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: Corporate presentation

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

2026-03-26T11:30:11.000Z - 3 months ago

Tonix Pharmaceuticals doses first patient in TNX-1900 study

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: Conference presentation

Mar 23, 2026, 4:32 PM EDT - 3 months ago

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

Mar 18, 2026, 4:58 PM EDT - 3 months ago

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Mar 17, 2026, 4:35 PM EDT - 3 months ago

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 12, 2026, 5:30 PM EDT - 3 months ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Annual report: Q4 2025

Mar 11, 2026, 1:00 PM EDT - 3 months ago

Tonix Pharmaceuticals Holding Transcript: Life Sciences Virtual Investor Forum

2026-03-10T12:36:35.000Z - 3 months ago

Tonix Pharmaceuticals announces presentations on Tonmya

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Mar 9, 2026, 4:30 PM EDT - 3 months ago

Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 4:30 PM EDT - 3 months ago

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-03-05T21:50:16.000Z - 4 months ago

Tonix Pharmaceuticals publishes TNX-102 SL data in journal

Mar 5, 2026, 4:15 PM EST - 4 months ago

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Mar 4, 2026, 11:10 AM EST - 4 months ago

Tonix Pharmaceuticals Holding Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 4:30 PM EST - 4 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

2026-03-03T11:06:52.000Z - 4 months ago

Tonix Pharmaceuticals approved to list on Nasdaq Global Select Market

Mar 3, 2026, 6:00 AM EST - 4 months ago

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Feb 25, 2026, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

2026-01-30T12:05:22.000Z - 5 months ago

Tonix Pharmaceuticals presents Phase 3 data on Tonmya

Jan 30, 2026, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Jan 6, 2026, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

2025-12-29T13:00:46.000Z - 6 months ago

Tonix prices 615,025 shares at $16.26 in registered direct offering

Dec 29, 2025, 7:57 AM EST - 6 months ago

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Dec 29, 2025, 7:45 AM EST - 6 months ago

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Dec 16, 2025, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Dec 9, 2025, 7:00 AM EST - 7 months ago

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

Nov 24, 2025, 7:00 AM EST - 7 months ago

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Nov 17, 2025, 7:00 AM EST - 7 months ago

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

Nov 13, 2025, 10:00 AM EST - 8 months ago

Tonix Pharmaceuticals Holding Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 10:00 AM EST - 8 months ago

Tonix Pharmaceuticals Holding Slides: FY 2025

Nov 10, 2025, 4:15 PM EST - 8 months ago

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 10, 2025, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals Holding Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals Holding Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Oct 28, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Oct 27, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 22, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 21, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 17, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Oct 14, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Oct 9, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Oct 2, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Sep 30, 2025, 8:30 AM EDT - 9 months ago

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Sep 29, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Sep 29, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Sep 18, 2025, 8:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Sep 18, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Holding Slides: Corporate Presentation

Sep 17, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Sep 8, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Sep 4, 2025, 1:35 PM EDT - 10 months ago

Tonix Pharmaceuticals Holding Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Holding Registration statement: Registration Filing

Aug 28, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025

Aug 18, 2025, 8:30 AM EDT - 11 months ago

Tonix Pharmaceuticals Holding Transcript: FDA Announcement

Aug 18, 2025, 8:30 AM EDT - 11 months ago

Tonix Pharmaceuticals Holding Press release: FDA Announcement

Aug 18, 2025, 8:30 AM EDT - 11 months ago

Tonix Pharmaceuticals Holding Slides: FDA Announcement

Aug 15, 2025, 3:50 PM EDT - 11 months ago

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

JuggernautRaider Jun. 29 at 3:09 AM

6 · Reply

glbeacher Jun. 29 at 3:03 AM

$TNXP f u to stino. you are living in a dreamworld.

0 · Reply

glbeacher Jun. 29 at 2:47 AM

$TNXP F U jugger. we don't need your worthless data and sure don't need to pay for it. maybe a penny, loser.

0 · Reply

JuggernautRaider Jun. 29 at 1:23 AM

1 · Reply

Mstrong87 Jun. 29 at 12:25 AM

$TNXP

0 · Reply

Hadog78 Jun. 28 at 10:40 PM

$TNXP

0 · Reply

gc358 Jun. 28 at 9:03 PM

$TNXP Ok, you're officially blocked. You have posted the same message at least 5 times to 5 other stocks from what I can see on the GALT board. You're obviously spamming.

2 · Reply

WARBUD Jun. 28 at 8:48 PM

1 · Reply

Bobear12 Jun. 28 at 7:34 PM

0 · Reply

Willy_Nilly Jun. 28 at 5:30 PM

1 · Reply

JRoc16 Jun. 28 at 5:17 PM

$TNXP

0 · Reply

JRoc16 Jun. 28 at 5:16 PM

$TNXP Lets see some PM news tomorrow and get this train rolling !

0 · Reply

JRoc16 Jun. 28 at 5:08 PM

$TNXP Pack your bags Bears !

0 · Reply

Duediligence20 Jun. 28 at 5:01 PM

$TNXP

0 · Reply

DeepBlueCyan Jun. 28 at 4:55 PM

$TNXP @Astupidmonkey I know that you are just collecting data from different posts and put them together in a table to help others. That is appreciated. Now, for all readers, you should always be careful to check free information. I looked over the table. Up to the week ending 05/22, the data is self-consistent. This means that the mechanism used to make that data remains the same through that period. This is good although the veracity of the data still must be verified by a different means. On the other hand, starting from the week ending 05/29, the data look as if they were created with a different mechanism every week. For example, the "TRx $ (000s)" column multiplied by 52 should equal to the "Implied Annual Gross Run". But for the week of 05/29, it was 58,864 calculated vs 45,298 displayed. Inconsistencies like that mean some sort of messing around by the people creating those numbers. You can decide for yourself what that was for for the last three sets of numbers.

0 · Reply

dxxxx Jun. 28 at 4:04 PM

$TNXP Don't let your Grade 2 sons or daughters know your true math skill. Check the data sets some one fabricated, posted and get applauded. LOL. $TNXP is an easy 10baggers not bc someone misleads on data sets or something else, but all known factors: 11m patients, of whom mostly unsatisfied with the existing treatments, or out of 15m prescriptions written each year, if Tonmya can be written in prescription about only 5% of that, there will be 10baggers. Then you have to consider the rich pipelines; some of which are very unique such as Lyme program; then plenty cash on hand. Of course dilution LOL Market is looking forward, not backward. Now check how that applauded data sets is so ridiculous: [byt if yu want to calculate: 806 prescriptions per week x 52weeks x $1620 per prescription = 859 prescriptions per week x 52weeks x $1620 per prescription =]

1 · Reply

Hoppanin Jun. 28 at 3:02 PM

$TNXP First posts Dxxx-head has ever made are today to bash TNXP without substantive arguments? Okay, shorting A$$🤡 BLOCKED! 💩🚽

0 · Reply

dxxxx Jun. 28 at 12:57 PM

$TNXP Totally fabricated: you even not bothered to ask a grade 2 pupil to have a basic math check or you are just that capable. Even worse so many you readers clapped their hands. Man the collective intelligence of $TNXP retail investors are at the level as good as Seth manages this company.

4 · Reply

Rungreen Jun. 28 at 12:22 PM

$TNXP https://seekingalpha.com/news/4607308-tonix-maplight-new-strong-buys-raymond-james

0 · Reply

Imno1 Jun. 28 at 12:22 PM

$TNXP

0 · Reply

dxxxx Jun. 28 at 12:09 PM

$TNXP just dipped in this board for a moment, I felt is completely waste of my time: too many little egos who think they can influence the market for their gain, probably swing trades. LOL. Big good bye!

2 · Reply

JuggernautRaider Jun. 28 at 10:39 AM

$TNXP yet another example of poor leadership by Seth since Tonmya’s approval. He’s attending conferences on the Lyme disease pipeline asset - which has an INCREDIBLY LOW net present value (NPV) @alphaonetrading - instead of selling doctors on Tonmya. The doctors who I have talked to about Tonmya have loved the concept. Did you know that long term exposure to cyclobenzaprine is dangerous for elderly patients and may lower your IQ? 🧠 I sure didn’t, but I get why now that I tried some myself after a doctor prescribed the old cyclobenzaprine. 🤕 WE THE SHAREHOLDERS… are growing impatient, Doctor Lederman and the board. 😡

1 · Reply

Market Cap	210.74M
Revenue (ttm)	13.11M
Net Income (ttm)	-124.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-946.00%
Debt to Equity Ratio	0.00

Volume	1,608,800
Avg Vol	497,148
Day's Range	N/A - N/A
Shares Out	15.94M
Stochastic %K	86%
Beta	1.67
Analysts	Strong Sell
Price Target	$42.20